Clinically reviewed by Dr. Pipat Finn, M.D., Senior Doctor, Doctor Pattaya.
Last reviewed: October 2026
GLP-1 receptor agonists can return blood sugar to normal in people with prediabetes, and clinical trials show meaningful reductions in HbA1c and fasting glucose. However, this effect is largely drug-dependent. Blood sugar often rises again after stopping the medication unless significant lifestyle changes are maintained. The evidence supports GLP-1 therapy as a powerful tool for prediabetes management, not a permanent cure.
You had your bloods done before the trip, or maybe a routine check here in Thailand turned up a number your doctor flagged. Your HbA1c sits somewhere between normal and full diabetes. You are not diabetic yet, but the trajectory is heading the wrong way. Now you are sitting in Pattaya, wondering what you can actually do about it.
GLP-1 receptor agonists such as semaglutide, and dual GIP/GLP-1 receptor agonists such as tirzepatide, have changed what is possible for people in your position. The trial data is genuinely impressive. But the question worth asking honestly is whether reversal means gone for good, or gone while the drug is doing the work. Here is what the evidence actually shows, what realistic expectations look like, and how to get started if you are here in Pattaya and want to act now.

What Prediabetes Actually Means, and Why the Threshold Matters
Prediabetes is not a single thing. There are two overlapping patterns. Impaired fasting glucose means your blood sugar is elevated after an overnight fast, before you eat anything. Impaired glucose tolerance means your blood sugar climbs too high after a meal and stays up too long.
The standard thresholds used in international guidelines are an HbA1c between 5.7% and 6.4%, fasting plasma glucose between 5.6 and 6.9 mmol/L, or a two-hour glucose between 7.8 and 11.0 mmol/L after a glucose load. These are not arbitrary lines. They mark the zone where the risk of progressing to type 2 diabetes rises sharply, and where early action has the most impact.
Why does this matter for GLP-1 therapy? The two patterns have different mechanisms. Impaired fasting glucose reflects excess glucose production by the liver overnight. Impaired glucose tolerance reflects a sluggish insulin response after eating. GLP-1 agonists address both, which is one reason they work across the full prediabetes range.
How GLP-1 Agonists Improve Blood Sugar in Prediabetes
GLP-1, glucagon-like peptide-1, is a hormone your gut releases after you eat. It prompts your pancreas to produce insulin, tells your liver to slow down glucose release, and reduces the rate at which your stomach empties. In people with prediabetes, this system is blunted. GLP-1 receptor agonists amplify it.
The practical result is smaller blood sugar spikes after meals, reduced overnight glucose output from the liver, and a better insulin response overall. Weight loss adds another layer. Even modest reductions in body weight reduce insulin resistance substantially.
You do not need to understand the mechanism in depth to benefit from the treatment. What matters is that GLP-1 agonists are working on several fronts at once, not just suppressing appetite. You can read more about how this applies to GLP-1 therapy for prediabetes and weight management on our dedicated page.

What the Clinical Trials Actually Show
The SCALE trial, using liraglutide in people with obesity and prediabetes, showed that a meaningful proportion of participants returned to normal blood sugar during treatment. The SURMOUNT-1 trial, using tirzepatide, showed even larger effects, with around 95% of participants who had prediabetes at baseline achieving normal blood sugar by week 72, compared with around 62% on placebo.
The STEP trials confirmed semaglutide’s effect on blood glucose markers in people without full diabetes. HbA1c reductions were consistent across trials, and fasting plasma glucose dropped alongside body weight.
The honest read of this data: GLP-1 agonists work. They work better than most lifestyle interventions alone for people who have metabolic syndrome or significant insulin resistance. The effect on HbA1c and fasting glucose is real and clinically significant.
GLP-1 Prediabetes Reversal vs Remission: Setting Honest Expectations
Here is the part that often gets glossed over. The trials showing impressive normalisation rates are measuring outcomes while patients are still on the drug. Data from the SURMOUNT-4 trial, which withdrew tirzepatide after an initial treatment period, showed partial relapse. Weight and cardiometabolic markers, including blood sugar, moved back toward baseline ranges for many participants after stopping the drug.
This does not mean the drug failed. It means the underlying tendency toward insulin resistance does not disappear permanently just because the medication normalised your numbers for a period. Durable remission, meaning normal blood sugar without ongoing medication, appears more achievable in people who also made sustained lifestyle changes during treatment, lost weight, and kept it off.
The practical message is straightforward. GLP-1 therapy gives you a powerful window. Use it to build the habits that make some of that benefit stick. The drug and the lifestyle work better together than either does alone.
Who Is a Good Candidate for GLP-1 Therapy in Prediabetes
Not everyone with a borderline HbA1c needs a GLP-1 injection. The strongest candidates are people who have prediabetes alongside overweight or obesity, metabolic syndrome (elevated blood pressure, abnormal lipids, central adiposity together), or a strong family history of type 2 diabetes with difficulty achieving change through diet alone.
GLP-1 agonists are not appropriate for everyone. They are generally avoided in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Active pancreatitis is a reason not to use or to stop these medications, and anyone with a history of pancreatitis needs careful assessment before starting. Anyone with significant kidney or liver disease needs careful assessment before starting. These are the reasons a proper clinical assessment matters before prescribing.
Metformin is a cheaper, well-studied alternative for diabetes prevention. For patients with overweight and prediabetes, though, GLP-1 agonists offer broader cardiometabolic risk reduction, including effects on blood pressure and lipids, that metformin does not match. A proper assessment helps determine which fits your situation.
Getting Started with GLP-1 for Prediabetes in Pattaya
If you are living here as an expat or on an extended stay, access is more straightforward than you might expect. At Doctor Pattaya, the first step is a consultation and a baseline blood panel: HbA1c, fasting plasma glucose, a full lipid panel, kidney function, liver enzymes, and TSH, a thyroid marker relevant to GLP-1 safety. Results are typically available same day or next day.
If you are eligible, treatment starts at a low dose and increases gradually over several weeks. This stepped titration is not optional. It is how you minimise nausea and GI side effects, which are the main reason people stop early. Most patients tolerate the drug well once the titration is handled properly.
For patients staying near Jomtien Beach or down toward Pratumnak Hill, in-clinic visits and follow-up appointments are easy to arrange without disrupting your stay.
Managing Side Effects During Dose Titration
The most common side effects are nausea, mild vomiting, and loose stools, usually during the first few weeks at each new dose level. These are not a sign something is wrong. They are how most people experience the drug stepping up.
A few practical points. Take your injection on the same day each week, at a consistent time. Eat smaller meals. Avoid high-fat foods during the first weeks at a new dose. Nausea usually settles within a week or two at a stable dose. Do not push the titration faster than your prescriber recommends.
Seek medical attention if you develop severe abdominal pain radiating to your back, persistent vomiting that stops you keeping fluids down, or signs of an allergic reaction. These are not typical adjustment effects and need same-day review.
Monitoring Your Progress
HbA1c reflects roughly three months of blood sugar history, so a retest at around 12 weeks is your first meaningful check. Many patients also notice lower fasting glucose readings before their HbA1c shifts, because fasting glucose responds more quickly.
Continuous glucose monitoring, a small sensor worn on the arm that tracks blood sugar in real time, can be useful for patients who want to see how specific foods and activities are affecting them. It is not mandatory, but some patients find it motivating.
Repeat testing at three and six months is standard. Doctor Pattaya offers in-house lab testing so you are not navigating the Thai public hospital system for a basic blood panel.
Lifestyle Alongside GLP-1: Why the Combination Matters
GLP-1 therapy works best as a catalyst. The drug reduces appetite, lowers blood sugar, and makes it easier to lose weight. But the habits you build while on it determine whether any of that lasts after you stop.
Prioritise protein and fibre at meals. Reduce refined carbohydrates and sugary drinks. Aim for regular moderate activity, anything that gets you moving consistently. Walking along Jomtien Beach counts. So does swimming. The specific activity matters less than the consistency.
The patients who do best long-term use the appetite suppression the drug provides to genuinely change their eating patterns, not just eat less of the same things. That is what converts drug-dependent normalisation into something more durable.
If your blood sugar is in the prediabetes range and you are in Pattaya, you do not need to wait until you are back home to get this sorted. Doctor Pattaya offers same-day consultations and full metabolic blood panels, available 24 hours a day. We can assess whether GLP-1 therapy is right for you, run your baseline tests, and start a properly supervised titration if you are a candidate. Walk in or call ahead. We cover South Pattaya, Jomtien, Pratumnak, and the wider area, including hotel and home visits.
Frequently Asked Questions
References
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022.
- Pi-Sunyer X, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). New England Journal of Medicine, 2015.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021.
- American Diabetes Association. Standards of Care in Diabetes 2024 — Classification and Diagnosis of Diabetes. Diabetes Care, 2024.
- Diatribe. Zepbound Reversed Prediabetes, Prevented Progression to Type 2 for Nearly Everyone, Study Shows. 2024.
The information in this article is for educational purposes only and does not constitute medical advice. It should not be used to self-diagnose or replace a consultation with a qualified physician. If you have concerns about your health, contact a licensed medical professional. For appointments at Doctor Pattaya, visit doctorpattaya.com.


